Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Impact · against what's priced in

Rhythm Pharmaceuticals receives a positive catalyst from the FDA approval of IMCIVREE for acquired hypothalamic obesity. This expands the addressable market by approximately 10,000 U.S. patients and establishes the company as the sole provider of a targeted therapy for this indication.

RYTM+0.70

No priced-in read yet